Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases.

Medical oncology (Northwood, London, England) - 1 Jul 2015

Pietrantonio Filippo, Mazzaferro Vincenzo, Miceli Rosalba, Cotsoglou Christian, Melotti Flavia, Fanetti Giuseppe, Perrone Federica, Biondani Pamela, Muscarà Cecilia, Di Bartolomeo Maria, Coppa Jorgelina, Maggi Claudia, Milione Massimo, Tamborini Elena, de Braud Filippo

Abstract excerpt

Neoadjuvant chemotherapy (NACT) prior to liver resection is advantageous for patients with colorectal cancer liver metastases (CLM). Bevacizumab- or cetuximab-based NACT may affect patient outcome and curative resection rate, but comparative studies on differential tumour regression grade (TRG) associated with distinct antibodies-associated regimens are lacking. Ninety-three consecutive patients received NACT...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bevacizumab

Share to Cetuximab

Share to Disease-Free Survival

Share to Hepatectomy

Share to Liver Neoplasms

Share to Neoadjuvant Therapy

Source

Identifiers

PMID: 26003673
DOI: 10.1007/s12032-015-0638-3

Genes

KRAS
TRG

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases.PMID 26003673Read ↗

KRAS status and outcome of liver resection after neoadjuvant chemotherapy including bevacizumab.Semantic proximity Read ↗

Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.Semantic proximity Read ↗

KRAS status and outcome of liver resection after neoadjuvant chemotherapy including bevacizumab (Br J Surg 2012; 99: 1575-1582).Semantic proximity Read ↗

Prognostic assessment of resected colorectal liver metastases integrating pathological features, RAS mutation and Immunoscore.Semantic proximity Read ↗

Impact of Multidisciplinary Tumour Boards (MTB) on the clinicopathological characteristics and outcomes of resected colorectal liver metastases across timeSemantic proximity Read ↗

Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis.Semantic proximity Read ↗

RAS mutations predict radiologic and pathologic response in patients treated with chemotherapy before resection of colorectal liver metastases.Semantic proximity Read ↗

Anatomical resection improves relapse-free survival in colorectal liver metastases in patients with KRAS/NRAS/BRAF mutations or right-sided colon cancer: a retrospective cohort study.Semantic proximity Read ↗

Anti-EGF Receptor-Based Conversion Chemotherapy in RAS Wild-Type Colorectal Cancer Patients: Impact on Survival and Resection Rates.Semantic proximity Read ↗

Resectability and resection rates of colorectal liver metastases according to RAS and BRAF mutational status: prospective study.Semantic proximity Read ↗

Hepatectomy versus systemic therapy for liver-limited BRAF V600E-mutated colorectal liver metastases: multicentre retrospective study.Semantic proximity Read ↗

Differential prognosis of metastatic colorectal cancer patients post-progression to first-line triplet chemotherapy plus bevacizumab, FIr-B/FOx, according to second-line treatment and KRAS genotype.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.